Form 8-K - Current report:
SEC Accession No. 0001213900-25-028366
Filing Date
2025-04-03
Accepted
2025-04-03 07:05:17
Documents
16
Period of Report
2025-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0236970-8k_moonlake.htm   iXBRL 8-K 34686
2 PRESS RELEASE, DATED APRIL 3, 2025 ea023697001ex99-1_moonlake.htm EX-99.1 38967
3 GRAPHIC ex99-1_001.jpg GRAPHIC 10471
4 GRAPHIC ex99-1_002.jpg GRAPHIC 18347
  Complete submission text file 0001213900-25-028366.txt   300600

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE mltx-20250331.xsd EX-101.SCH 3020
6 XBRL LABEL FILE mltx-20250331_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE mltx-20250331_pre.xml EX-101.PRE 22362
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0236970-8k_moonlake_htm.xml XML 3551
Mailing Address DORFSTRASSE 29 ZUG V8 6300
Business Address DORFSTRASSE 29 ZUG V8 6300 41 41 510 8022
MoonLake Immunotherapeutics (Filer) CIK: 0001821586 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39630 | Film No.: 25807494
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)